clinical trial · NCT06741969
Nipocalimab in Moderate to Severe Sjogren's Disease
Janssen Research & Development, LLC·phase3·active not recruiting·n = 655
Sjogrens SyndromeNipocalimabPlaceboStandard of care treatment
brief summary
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
started
Dec 4, 2024
primary completion
Jan 1, 2028
completion
May 18, 2029
last updated
Jul 31, 2026
detailed description
This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (\>=) 18 years of age with moderate to severe SjD.
official title
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults With Moderate to Severe Sjogren's Disease (SjD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol